A carregar...
PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia
Imatinib mesylate is highly effective in newly diagnosed chronic myeloid leukemia (CML), but BCR/ABL (breakpoint cluster region/abelson murine leukemia)–positive progenitors persist in most patients with CML treated with imatinib mesylate, indicating the need for novel therapeutic approaches. In thi...
Na minha lista:
| Main Authors: | , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
© 2005 by The American Society of Hematology
2005
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1895078/ https://ncbi.nlm.nih.gov/pubmed/15657179 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2004-09-3534 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|